secwatch.observer — SEC 8-K summary
======================================

Issuer:     Envoy Medical, Inc. (COCH)
CIK:        0001840877
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001213900-24-067387
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Envoy Medical Q2 revenue $68k, cash $1.7M; Acclaim CI pivotal trial goal by end-2024
--------------------------------------------------------------------------------

- Revenue $68k (Q2 2024) vs $63k prior year; revenue from two Esteem units offset by battery sales decline.
- R&D expenses rose $438k to $2.6M due to increased headcount for Acclaim CI pivotal study preparation.
- Three EFS participants completed 18-month follow-up; all show CIQOL improvement, no SADEs/UADEs reported.
- System noise mitigations implemented; two participants used hearing aid with Acclaim for better SNR.
- Company maintains goal to submit IDE in coming months and start pivotal trial by year-end 2024; commercialization targeted by end-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840877/000121390024067387/0001213900-24-067387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840877/000121390024067387/ea0211068-8k_envoy.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-067387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer